Praxis für Kardiologie

This site focuses on cardiovascular diseases, with studies aimed at better understanding and managing conditions that affect the heart and blood vessels. The research is centered on testing new treatment approaches and improving long-term outcomes for people at risk of serious cardiovascular events.

• Prevention of stroke and systemic embolism in atrial fibrillation
• Reducing major cardiovascular events in people with atherosclerotic cardiovascular disease
• Evaluating therapies for patients with hypertension and established cardiovascular risk

The trial portfolio in Markkleeberg includes efforts to improve both prevention and treatment, with a strong emphasis on lowering the risk of heart, brain, and vascular complications.

Several trials at the site examine ways to improve LDL cholesterol control in people with elevated cardiovascular risk. These studies are designed to assess whether newer therapies can help patients reach target cholesterol levels more effectively than current care alone.

• Treatment of hypercholesterolemia and hyperlipidemia
• Improving cholesterol control in atherosclerotic cardiovascular disease
• Testing new options to lower LDL-C and reduce future risk

This area includes research on whether novel medicines can support better risk reduction for patients who need stronger lipid management.

The site also studies different forms of heart failure, including patients with reduced, preserved, or mildly reduced heart function. These trials aim to find treatments that can lower the chance of worsening symptoms, hospital visits, and cardiovascular death.

• Therapies for Heart Failure With Reduced Ejection Fraction
• Research in HFpEF and HFmrEF with obesity
• Prevention of worsening heart failure and related hospitalizations

The research reflects a broad effort to improve care for people living with symptomatic heart failure and to support more effective long-term disease control.

Another important focus is the link between type 2 diabetes, obesity, blood pressure, and cardiovascular disease. Trials in this area are looking at whether combining treatments can better protect patients from heart failure and other serious complications.

• Type 2 diabetes with hypertension and established cardiovascular disease
• Obesity in people with heart failure
• Lowering the risk of heart failure events and cardiovascular death

This research supports a more integrated approach to cardiometabolic care, especially for patients with overlapping risk factors.